We are on a mission to
outsmart cancer resistance.

Theseus is developing next-generation kinase inhibitors to transform the way cancer is treated.

Learn Moredown

Our investigational oncology therapies are designed to address treatment-resistant cancer mutations.

Working to deliver best-in-class pan-variant Tyrosine Kinase Inhibitors (TKIs) to cancer patients.

We are developing a pipeline of TKIs designed to inhibit all major cancer causing and drug resistance mutations in clinically significant protein kinases.